Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.

Soleno Therapeutics’ stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the company.

Source

MarketWatch

Opens original article in a new tab

‘I worked very hard’: I’m 71 and have $6 million after scrimping and saving. My son, 33, wants money for a house. Do I say yes?

“My son is 33 years old, married, with an 18-month-old baby and another baby due in September.”

38 minutes agoRead more →

Yahoo Finance

41 minutes agoRead more →

Bloomberg Markets

A Barings LLC private credit fund capped redemptions after investors asked to pull out 11.3% of the shares in the first quarter.

about 1 hour agoRead more →

Yahoo Finance

about 1 hour agoRead more →